批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2022/10/31 |
SUPPL-8(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2022/02/23 |
SUPPL-7(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2018/06/18 |
SUPPL-4(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2016/11/07 |
ORIG-1(原始申请) |
Approval |
Type 5 - New Formulation or New Manufacturer |
STANDARD
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
活性成分:DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE 剂型/给药途径:TABLET, EXTENDED RELEASE;ORAL 规格:20MG;20MG 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
209661 |
001 |
NDA |
BONJESTA |
DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE |
TABLET, EXTENDED RELEASE;ORAL |
20MG;20MG |
Prescription |
Yes |
Yes |
AB |
2016/11/07
|
DUCHESNAY |
212472 |
001 |
ANDA |
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE |
DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE |
TABLET, EXTENDED RELEASE;ORAL |
20MG;20MG |
Discontinued |
No |
No |
AB |
2022/03/01
|
ACTAVIS LABS FL INC |